What is the indication for the 11 mg nasal spray formulation of sumatriptan (AVP‑825/ONZETRA Xsail)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Indication for ONZETRA Xsail (AVP-825)

ONZETRA Xsail is indicated for the acute treatment of migraine with or without aura in adults. 1

Specific Approved Use

The 11 mg nasal spray formulation of sumatriptan (delivered as ONZETRA Xsail) is FDA-approved specifically for:

  • Acute migraine treatment in adults with established migraine diagnosis
  • Migraine with or without aura
  • Not for migraine prevention - this is an abortive therapy only 1

Key Limitations of Use

Critical diagnostic requirement: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with ONZETRA Xsail, reconsider the diagnosis before treating subsequent attacks. 1

Not indicated for:

  • Prevention of migraine attacks
  • Treatment of cluster headache (safety and effectiveness not established) 1

Dosing Context

The complete dose is 22 mg total (delivered as two 11 mg nosepieces, one per nostril) using the breath-powered Xsail delivery device. 1 This delivery system deposits low-dose sumatriptan powder in the upper posterior nasal cavity for rapid absorption, providing earlier onset of efficacy compared to oral sumatriptan. 2, 3, 4

Clinical Positioning

According to current guidelines, triptans like sumatriptan are reserved for moderate to severe migraines or mild to moderate migraines unresponsive to NSAIDs or analgesics. 5, 6 The intranasal formulation is particularly advantageous when significant nausea or vomiting accompanies the migraine, making non-oral routes preferable. 5

The most recent 2025 ACP guideline recommends adding a triptan to an NSAID (or acetaminophen when NSAIDs are contraindicated) for patients who don't achieve sufficient pain relief with NSAIDs/acetaminophen alone. 7

References

5
Guideline

management of the acute migraine headache.

American family physician, 2002

Related Questions

How should sumatriptan nasal spray be administered for acute migraine relief?
How do I order sumatriptan nasal spray 11 mg?
What fast‑acting acute rescue medication is recommended for a patient on migraine preventive therapy who experiences occasional breakthrough migraine attacks?
How should I manage a patient with HbA1c 9.2% and weight loss who is currently taking empagliflozin (Jardiance) and metformin 500 mg?
How do I order sumatriptan nasal spray 11 mg?
What is the appropriate adjuvant systemic therapy for a patient with a stage IV moderately differentiated mucin‑secreting colon adenocarcinoma (pT4a pN1c pM1a) with positive proximal, distal, and circumferential resection margins, lymphovascular and perineural invasion, high tumor budding, and two pericolonic adipose tissue nodules?
What are the common side effects of systemic corticosteroid therapy and the recommended monitoring and management strategies?
What is the maximum dosing frequency for a 20 mg sumatriptan nasal spray in acute migraine treatment?
Does a patient with a pericardial effusion and a decreasing elevated troponin level require further ischemic evaluation?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.